Lupin receives EIR from U.S. FDA for its Dabhasa Facility

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility located in Dabhasa, Gujarat. The EIR was issued post the last inspection of the facility conducted from April 8 to April 12, 2024. The inspection concluded with no observations and the facility receiving an inspection classification of "No Action Indicated" (NAI). The facility is a part of Lupin Manufacturing Solutions (LMS), which is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and Contract Development and Manufacturing Operations.

"We are pleased to receive the EIR for Dabhasa from the U.S. FDA," said Nilesh Gupta, Managing Director, Lupin. "This achievement is in line with our continued focus and commitment to maintaining the highest standards of quality and compliance in all aspects of our operations. This reaffirms our pursuit of delivering high-quality, affordable healthcare solutions to our patients globally."

Shares of Lupin Limited was last trading in BSE at Rs. 1797.10 as compared to the previous close of Rs. 1816.90. The total number of shares traded during the day was 6755 in over 905 trades.

The stock hit an intraday high of Rs. 1826.95 and intraday low of 1794.75. The net turnover during the day was Rs. 12196657.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 EIR USFDA DabhasaFacility